Prothena’s lead drug NEOD001 just imploded in 2 late-stage studies — and there’s nothing left to salvage

Prothena’s lead drug has decisively failed a crucial Phase IIb study for rare, second-line cases of AL amyloidosis. And after concluding that their Phase III for frontline use is also headed to failure, the biotech’s executive team is scrapping the whole program.